ReviewSexually transmitted diseases2020
A Narrative Review of Current Challenges in the Diagnosis and Management of Bacterial Vaginosis.
Review in Sexually transmitted diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 65 citations in OpenAlex.
- Bacterial Vaginosis [BV] knowledge, attitudes and behavioural changes after BV diagnosis among women enrolled in a clinical trial in Boston, USA and Vulindlela, South Africa: a qualitative study.BMC women's health · 2025Trial
- Intravaginal lactic acid gel versus oral metronidazole for treating women with recurrent bacterial vaginosis: the VITA randomised controlled trial.BMC women's health · 2023Trial
- Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Cost-effectiveness analysis of bacterial vaginosis screening strategies in women attempting for natural conception.Cost effectiveness and resource allocation : C/E · 2026Article
- Microbiota Transplantation as a Future Novel Therapeutic Strategy Approach.Diseases (Basel, Switzerland) · 2026Review
- Inflammation at the maternal-fetal interface: a perspective on interacting risk factors for preterm birth in sub-Saharan African women living with HIV.Frontiers in immunology · 2026Review
- Diagnostic performance of deep learning-based vaginal microecological morphology assessment for bacterial vaginosis and vulvovaginal candidiasis.Frontiers in microbiology · 2026Article
- Randomized trial of multi-strainContemporary clinical trials communications · 2025Article
- Applications and challenges of 3D printing in female reproductive system research.3D printing in medicine · 2025Article
- Understanding Patient Perceptions of Bacterial Vaginosis Treatments: Mixed Methods Sentiment Analysis Study of Online Drug Review Forums.Online journal of public health informatics · 2025Article
- Vaginal pharmacomicrobiomics modulates risk of persistent and recurrent bacterial vaginosis.NPJ biofilms and microbiomes · 2025Review
- Bacterial vaginosis.Nature reviews. Disease primers · 2025Review
- Genome-scale metabolic network reconstruction analysis identifies bacterial vaginosis-associated metabolic interactions.Nature communications · 2025Article
- The activity of cell-free supernatant ofFrontiers in cellular and infection microbiology · 2025Article
- Microbiota transplantation.Heliyon · 2024Review
- The cAMP receptor protein from Gardnerella vaginalis is not regulated by ligands.Communications biology · 2024Article
- Sexual transmission of urogenital bacteria: whole metagenome sequencing evidence from a sexual network study.mSphere · 2024Article
- Evaluation of the activity of antimicrobial peptides against bacterial vaginosis.Open life sciences · 2024Article
- A manifold-based framework for studying the dynamics of the vaginal microbiome.NPJ biofilms and microbiomes · 2023Article
- Development of 3D-printed vaginal devices containing metronidazole for alternative bacterial vaginosis treatment.International journal of pharmaceutics: X · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Despite the availability of a number of oral and intravaginal antibiotic medications for the treatment of bacterial vaginosis (BV), management of this condition remains challenging. Recurrent BV occurs in >50% of patients receiving guideline-recommended treatments. This may be due to persistence or resurgence of the BV biofilm after treatment cessation, failure to reestablish an optimal vaginal microbiome after treatment, reinfection from an untreated sexual partner, or a combination of these factors. Nonadherence to multidose BV therapies may potentially contribute to recurrent BV, although there are no published data that directly assess the role of nonadherence to poor treatment outcomes and recurrent BV. There is a need for studies of BV treatment adherence in real-world settings as well as studies to explore the relationship between treatment adherence and recurrence. This review explores challenges associated with diagnosing and treating BV, current multidose antibiotic treatment options, newer single-dose treatment options, and ways to potentially maximize treatment success for this common vaginal infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.